Swedish Biotech gets Orphan Drug Designation in Pediatric Colitis

InDex Pharmaceuticals has gotten a boost from the FDA for cobitolimod, which is in Phase II for the treatment of pediatric ulcerative colitis. Stockholm-based InDex Pharmaceuticals is working on treatments for ulcerative colitis based on toll-like receptors (TLRs), the subject ...

More From BioPortfolio on "Swedish Biotech gets Orphan Drug Designation in Pediatric Colitis"

Relevant Topics

Clincial TrialsIn a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

PediatricsPediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...